Bicara Therapeutics stockholders elect directors and ratify KPMG as auditor

Bicara Therapeutics Inc.

Elected Dr. Christopher Bowden and Dr. Carolyn Ng as Class II directors for three-year terms.
Bowden: 48,558,710 for, 5,145,418 withheld; Ng: 47,431,269 for, 6,272,859 withheld.
Ratified KPMG LLP as independent auditor for FY2026: 55,914,602 for, 8,815 against, 1,570 abstain.
85.25% of outstanding shares (55.9M of 65.6M) were present or represented at the meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Bicara Therapeutics Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-09 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

Proposal 2: Ratification of KPMG LLP The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows: Votes For Votes Against Votes Abstaining Ratification of appointment of KPMG LLP 55,914,602 8,815 1,570

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Bicara Therapeutics Inc. shareholders approved Election of Class II Directors at the 2026-06-09 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-09

Exact text from the filing

Proposal 1: Election of Directors The Company's stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows: Director Votes For Votes Withheld Broker Non-Votes Christopher Bowden, M.D. 48,558,710 5,145,418 2,220,859 Carolyn Ng, Ph.D. 47,431,269 6,272,859 2,220,859

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Bicara Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-042176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.